Fast and easy tumor detection with liquid biopsy

December 3, 2015 News BioVox

VITO and the Antwerp University Hospital (UZA) recently joined forces with 3 Flemish companies, Biocartis, RIC and Pharmafluidics for the project ‘Early Diagnosis by Easy Sampling’. The consortium received a grant of 2,2 million euros from the Flemish Agency for Innovation by Science and Technology (IWT) to develop innovative liquid biopsy tests for the diagnosis of cancer.

Unique to this project is that the analysis of the plasma samples, or liquid biopsies, is not limited to only freely circulating tumour DNA. Also other components in blood that potentially contain cancer-specific molecular information, can be used for molecular diagnostic testing.

The role of VITO is to characterize different plasma fractions on the protein level, using its Proteomics technology and evaluate which fractions have high diagnostic potential. The Proteomics team will especially focus on the extracellular vesicle fractions (exosomes) of the plasma and evaluate their diagnostic potential. Finally, the team will compare the fractionation methods, developed by Pharmafluidics, with the current golden standards for plasma fractionation.

With this grant, VITO confirms its position as a research partner in the field of diagnostic biomarker development and extends its portfolio both on the technology and the disease level.

By granting this budget, IWT affirms its belief in multidisciplinary partnerships that bring cutting-edge innovation in Flanders.


Avatar photo
BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter